Windtree Therapeutics Inc Stock Price, News & Analysis

Windtree Therapeutics, Inc. (NasdaqCM: WINT) has initiated an underwritten public offering of its common stock and warrants, intended to finance the advancement of its lead product, istaroxime, for acute heart failure, alongside other pipeline candidates. The offering is contingent on market conditions, with no guarantee on its completion or terms. Proceeds will also support a second phase 2b clinical trial and general corporate purposes. Oppenheimer & Co. Inc. and Ladenburg Thalmann & Co. Inc. are managing the offering, filed under Windtree's shelf registration statement.

Windtree Therapeutics (NasdaqCM: WINT) announced an extension of its collaboration with the University of Milan-Bicocca to develop new SERCA2a compounds aimed at treating chronic and acute heart failure. Over the next year, the focus will be on characterizing SERCA2a activators and their interactions with related proteins. This collaboration bolsters Windtree's SERCA2a program, which includes istaroxime, a dual-action agent currently in a Phase 2 study for acute decompensated heart failure and granted Fast Track designation by the FDA based on positive trial results.

Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced that CEO Craig Fraser will present at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021, at 10:40 AM ET. A live audio webcast will be available on Windtree's website, with a replay accessible for 30 days. Windtree is focused on developing therapies for acute cardiovascular and pulmonary disorders, including its lead candidate istaroxime for heart failure and AEROSURF® for respiratory distress in infants. For more details, visit www.windtreetx.com.

Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced that CEO Craig Fraser will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The company focuses on advancing late-stage interventions for acute cardiovascular and pulmonary disorders, including istaroxime for acute heart failure and AEROSURF® for respiratory distress in premature infants. A live audio webcast will be available on the company's website, with a replay for 30 days. For further details, visit www.windtreetx.com.

Windtree Therapeutics, Inc. (WINT) announced the issuance of U.S. Patent No. 10,874,818 for its aerosol delivery system (ADS) related to the AEROSURF device. This patent, effective until 2039, enhances their IP portfolio in aerosolized pulmonary surfactants. The redesigned ADS features improved ergonomics and reduced treatment interruptions, potentially improving clinical outcomes for patients with respiratory distress syndrome. CEO Craig Fraser expressed confidence in the company's ongoing efforts to strengthen its intellectual property across its product lines, including istaroxime for acute heart failure.

Windtree Therapeutics (NasdaqCM: WINT) announced the appointment of Dr. Evan Loh, Ms. Leslie Williams, and Dr. Rob Scott to its Board of Directors, following a board composition analysis to meet the company’s evolving needs. The new members bring extensive experience in drug development and commercialization. Former directors John Leone, Joseph Mahady, and Brian Schreiber will retire, leaving a seven-member board. CEO Craig Fraser expressed optimism about the new appointments aligning with Windtree’s late-stage trials for istaroxime and lucinactant, enhancing strategic growth.

Windtree Therapeutics, a biotechnology company focused on acute cardiovascular and pulmonary disorders, has appointed Dr. Joseph Soffer as Executive Director of Clinical Development. This appointment aims to bolster efforts in the istaroxime program, targeting acute heart failure. Dr. Soffer brings over 30 years of experience, previously serving as a Senior Medical Director at GlaxoSmithKline. In connection with his role, he has been granted a stock option to purchase 100,000 shares at a closing price determined on January 29, 2021.

Windtree Therapeutics, Inc. (NasdaqCM: WINT) has initiated its Phase 2 clinical trial, dosing the first patient with lucinactant for adult acute lung injury related to COVID-19 and ARDS. This synthetic KL4 surfactant aims to improve respiratory function and reduce mechanical ventilation time. The trial will enroll up to 20 patients at multiple U.S. sites, evaluating physiological changes and tolerability. With rising COVID-19 cases and a lack of approved ARDS therapies, the study is critical for developing effective treatments for severe respiratory conditions.

Windtree Therapeutics (WINT) reported a net loss of $9.0 million for Q3 2020, with an operating loss of $8.7 million. Research and development expenses rose slightly to $3.9 million, while general and administrative expenses increased to $4.8 million, partly due to severance costs. The company announced the dosing of the first patient in a Phase 2 clinical trial of istaroxime for cardiogenic shock and received FDA acceptance for a Phase 2 trial of KL4 surfactant in COVID-19 patients. Cash and cash equivalents stand at $22.4 million, sufficient for operations through at least the next 12 months.